CTOR

시간 외 거래: 1.06 0.01 +0.95%

Citius Oncology Inc (CTOR)

개요 뉴스 가격 이력 토론 예측

Relative Volume:

Citius Oncology Inc Stock (CTOR) Company Profile

Citius Oncology Inc

Healthcare (1067)

(908) 967-6677

11 COMMERCE DRIVE, CRANFORD

최신 SEC 제출 서류

CTOR's Discussions on Twitter

Compare CTOR vs TAK, TEVA, HLN, ZTS, VTRS

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
CTOR Citius Oncology Inc	1.05	111.05M	5.61M	-42.51M	-16.86M	-0.466
TAK Takeda Pharmaceutical Co Adr	18.86	60.23B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	39.19	45.71B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.26	40.72B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	71.05	29.36B	9.51B	2.64B	2.14B	6.0361
VTRS Viatris Inc	17.83	20.48B	14.57B	-296.50M	1.64B	-0.259

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2025-09-23	업그레이드	Maxim Group	Hold → Buy
2024-11-27	개시	Maxim Group	Buy

Citius Oncology Inc 주식(CTOR)의 최신 뉴스

Citius Oncology Inc (CTOR) 재무 분석

Citius Oncology Inc (CTOR)

Citius Oncology Inc Stock (CTOR) Company Profile

Compare CTOR vs TAK, TEVA, HLN, ZTS, VTRS

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Citius Oncology Inc 주식(CTOR)의 최신 뉴스

Citius Oncology (CTOR) Ticks Higher: Shares Climb 2.39% to $1.07 Near Key ResistanceMomentum Stock Picks - siam.in

CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill

CTXR Stock Price, Quote & Chart - ChartMill

Citius Pharmaceuticals at Moody Capital conference: launch gains traction By Investing.com - Investing.com UK

Citius Pharma CEO to speak at two New York conferences - Stock Titan

Citius Pharmaceuticals to Participate in September 2026 Investor Conferences - PR Newswire

Citius Oncology (CTOR) Slips 1.86% to $0.78 as Shares Press Against Key Support ZoneBPI Bull Confirmed - dars.gov.et

CITIUS ONCOLOGY, INC. SEC Filing (Aug 26, 2026) - Stock Titan

Citius (CTOR) Quarterly Results: The EPS Result Is Below Expectation in the Latest Session; Session Move: Shares Finish 2.02% Lower on the DayEPS Surprise History - vinanet.vn

Enterprise value to EBIT forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView

Armistice Capital Expands Citius Oncology (CTOR) Stake Despite Distress Signals - GuruFocus

Citius (CTOR) Quarterly Results: Reported EPS Misses Expectations in the Reported Period; After Results: The Market Price Advances 6.97% on the DayForward Guidance Trends - vinanet.vn

Citius Oncology Shares Slide 10% After Fiscal Q3 Revenue Misses Estimates Despite LYMPHIR Launch Gains - dars.gov.et

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum - Yahoo Finance

Citius Oncology stock tumbles 10% on revenue miss despite launch progress - Investing.com Australia

Citius Oncology (CTOR) Institutional Ownership 2026 $CTOR - MarketBeat

Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination - The Clinical Trial Vanguard

CTOR Q2 2026 Earnings: Pre-Revenue Loss Misses Badly, Yet Shares Jump 10%EBITDA Analysis - vinanet.vn

Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR) - simplywall.st

Citius Pharma Reports First LYMPHIR Revenue of $7.1M in Nine Months - Minichart

Citius Oncology Posts First Revenue from LYMPHIR Launch as Institutional Demand Surges 31% - Minichart

Citius Oncology (NASDAQ:CTOR) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat

Citius Oncology (CTOR) director Jonathan Peri files Form 3 showing no common shares - Stock Titan

Citius Pharma Q3 EPS beats estimate, sales miss by 72% - scanx.trade

Citius Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress - Intellectia AI

CTOR: LYMPHIR launch drove $7.1M revenue and 31% sequential vial order growth, with broad payer access - TradingView

Citius Oncology (CTOR) grows LYMPHIR sales but posts $41M nine-month loss - Stock Titan

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - PR Newswire

Citius Oncology (CTOR) Advances 5.5% to $0.87 as Buyers Defend Support ZoneInverse ETF Flow - vinanet.vn

Citius Oncology (CTOR) investor reports 9.99% beneficial ownership stake - Stock Titan

Citius Oncology appoints independent director Peri to board of directors - ROI-NJ

Citius Oncology appoints Jonathan Peri to board of directors By Investing.com - Investing.com Australia

People on the Move: Jonathan Peri, Ph.D., J.D., Joins Citius Oncology’s Board of Directors - BioBuzz

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri - Morningstar

Citius Pharmaceuticals expands Citius Oncology board to nine with appointment of Jonathan Peri - Traders Union

Form 8K Citius Oncology Inc For: 12 August By Investing.com - Investing.com South Africa

Citius Oncology adds independent director to expanded board - TipRanks

Citius Oncology Adds Jonathan Peri to Board as LYMPHIR Commercialization Advances - citybiz

Citius Oncology appoints Jonathan Peri to board of directors - Investing.com

Citius Oncology (CTOR) Expected to Announce Earnings on Tuesday - MarketBeat

Citius Oncology Inc (CTOR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Citius Oncology Inc expected to post a loss of 5 cents a shareEarnings Preview - TradingView

CTOR Q2 2026 Earnings: Deep EPS Miss Highlights Development-Stage Cash Burn ChallengesDividend Earnings Report - vinanet.vn

Citius Oncology of Cranford says commercial response to cancer treatment is strong - ROI-NJ

LYMPHIR orders rise 78% QoQ as Citius Oncology expands market access for CTCL treatment. - Pluang

Citius Oncology reports strong LYMPHIR U.S. launch momentum - TipRanks

Citius Oncology reports strong LYMPHIR commercial momentum - TipRanks

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment - PR Newswire

Citius Oncology (CTOR) Adds 3.22% as Shares Hold Above $0.56 SupportEarnings Quality Factor - careplusvn.com

CTOR|Citius Oncology Inc|Price:0.654|Chg%:+0.062 - TradingKey

Citius Oncology Inc (CTOR) 재무 분석

매출

순이익

현금흐름

주당 순 이익

CTOR과 유사한 종목